A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular PCV

Trial Profile

A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular PCV

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Verteporfin (Primary) ; Ranibizumab
  • Indications Choroid diseases
  • Focus Therapeutic Use
  • Acronyms EVEREST II
  • Sponsors Novartis
  • Most Recent Events

    • 01 Nov 2017 Primary endpoint (Complete polyp regression assessed by ICGA at Month 12) has been met, as per results published in the JAMA Ophthalmology.
    • 01 Nov 2017 Primary endpoint (Change from Baseline in in Visual Acuity (Letters) of the Study Eye to Month 12) has been met, as per results published in the JAMA Ophthalmology.
    • 01 Nov 2017 Results comparing safety and efficacy of combination therapy of ranibizumab and verteporfin photodynamic therapy, published in the JAMA Ophthalmology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top